Evidence map›Paper›PMID 29105198›Full record

ArticleBrain pathology (Zurich, Switzerland)2018

BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.

Nozomi Nakajima, Sumihito Nobusawa, Satoshi Nakata, Mitsutoshi Nakada, Tatsuya Yamazaki, Nozomi Matsumura, Kenichi Harada, Hadzki Matsuda, Nobuaki Funata, Shoichi Nagai and 5 more

Open access · greenAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.Archives of pathology & laboratory medicine · 2022
    Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers.International journal of molecular sciences · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Updates in IDH-Wildtype Glioblastoma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  18. The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.Laboratory investigation; a journal of technical methods and pathology · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Nozomi NakajimaDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Sumihito NobusawaDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.ORCID 0000-0001-9434-8400
Satoshi NakataDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Mitsutoshi NakadaDepartment of Neurosurgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Tatsuya YamazakiDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Nozomi MatsumuraDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Kenichi HaradaDepartment of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Hadzki MatsudaDepartment of Neurosurgery, Dokkyo Medical University, Mibu, Japan.
Nobuaki FunataDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Shoichi NagaiDepartment of Neurosurgery Faculty of Medicine, University of Toyama, Toyama, Japan.
Hideo NakamuraDepartment of Neurosurgery, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
Atsushi SasakiDepartment of Pathology, Saitama Medical University, Moroyama, Japan.
Jiro AkimotoDepartment of Neurosurgery, Tokyo Medical University, Tokyo, Japan.
Junko HiratoDepartment of Pathology, Gunma University Hospital, Maebashi, Japan.
Hideaki YokooDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Gunma University · JPKanazawa University · JPDokkyo Medical University · JPGunma University Hospital · JPKumamoto University · JPSaitama Medical University · JPTokyo Medical University · JPTokyo Metropolitan Komagome Hospital · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelioid glioblastoma (E-GBM) is a rare aggressive variant of IDH-wildtype glioblastoma newly recognized in the 2016 World Health Organization classification, composed predominantly of monotonous, patternless sheets of round cells with laterally positioned nuclei and plump eosinophilic cytoplasm. Approximately 50% of E-GBM harbor BRAF V600E, which is much less frequently found in other types of glioblastomas. Most E-GBM are recognized as primary/de novo lesions; however, several E-GBM with co- or pre-existing lower-grade lesions have been reported. To better understand associations between E-GBM and the lower-grade lesions, we undertook a histological and molecular analysis of 14 E-GBM, 10 of which exhibited lower-grade glioma-like components (8 E-GBM with co-existing diffuse glioma-like components, 1 E-GBM with a co-existing PXA-like component and 1 E-GBM with a pre-existing PXA). Molecular results demonstrated that the prevalence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions in E-GBM were 13/14 (93%), 10/14 (71%) and 11/14 (79%), respectively, and concurrent BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions were observed in 7/14 (50%) of E-GBM. These alterations were also frequently seen in the lower-grade lesions irrespective of the histology. Genetic analysis including array comparative genomic hybridization performed for 5 E-GBM with co- and pre-existing lower-grade components revealed that all molecular changes found in the lower-grade components were also observed in the E-GBM components, and additional changes were detected in the E-GBM components. In conclusion, E-GBM frequently exhibit BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions and these alterations tend to coexist in E-GBM. Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity.

Indexed as

AdolescentAdultAgedBrain NeoplasmsChildCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16FemaleGlioblastomaHomozygoteHumansMaleMiddle AgedMutationNeoplasm GradingPromoter Regions, GeneticBRAF protein, humanCDKN2A protein, humanCDKN2B protein, humanCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16Proto-Oncogene Proteins B-rafTelomeraseTERT protein, humanBRAFCDKN2A/Bdiffuse astrocytomaepithelioid glioblastomaTERT

Identifiers

PMID29105198
PMCPMC8028676
OpenAlexW2765572262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.